Literature DB >> 15846721

Inpatient versus other settings for detoxification for opioid dependence.

E Day1, J Ison, J Strang.   

Abstract

BACKGROUND: There are a complex range of variables that can influence the course and subjective severity of opioid withdrawal. There is a growing evidence for the effectiveness of a range of medically-supported detoxification strategies, but little attention has been paid to the influence of the setting in which the process takes place.
OBJECTIVES: To evaluate the effectiveness of any inpatient opioid detoxification programme when compared with all other time-limited detoxification programmes on the level of completion of detoxification, the intensity and duration of withdrawal symptoms, the nature and incidence of adverse effects, the level of engagement in further treatment post-detoxification, and the rates of relapse post-detoxification. SEARCH STRATEGY: Electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL - The Cochrane Library Issue 3, 2004); MEDLINE (January 1966-March 2004); EMBASE (January 1988-March 2004); PsycInfo (January 1967-March 2004); CINAHL (January 1982-March 2004). In addition the Current Contents, Biological Abstracts, Science Citation Index and Social Sciences Index were searched. SELECTION CRITERIA: Randomised controlled clinical trials comparing inpatient opioid detoxification (any drug or psychosocial therapy) with other time-limited detoxification programmes (including residential units that are not staffed 24 hours per day, day-care facilities where the patient is not resident for 24 hours per day, and outpatient or ambulatory programmes, and using any drug or psychosocial therapy). DATA COLLECTION AND ANALYSIS: All abstracts were independently inspected by two reviewers (ED & JI) and relevant papers were retrieved and assessed for methodological quality using Cochrane Reviewers' Handbook criteria. MAIN
RESULTS: Only one study met the inclusion criteria. This did not explicitly report the number of participants in each group that successfully completed the detoxification process, but the published data allowed us to deduce that 7 out of 10 (70%) in the inpatient detoxification group were opioid-free on discharge, compared with 11 out of 30 (37%) in the outpatient group. There was very limited data about the other outcomes of interest. AUTHORS'
CONCLUSIONS: This review demonstrates that there is no good available research to guide the clinician about the outcomes or cost-effectiveness of inpatient or outpatient approaches to opioid detoxification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846721     DOI: 10.1002/14651858.CD004580.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  9 in total

1.  Factors predicting completion in a cohort of opiate users entering a detoxification programme.

Authors:  Louise Mullen; Eamon Keenan; Joseph Barry; Jean Long; Deirdre Mulholland; Loretto Grogan; Ide Delargy
Journal:  Ir J Med Sci       Date:  2010-02-21       Impact factor: 1.568

Review 2.  Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

3.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

Review 4.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

Review 5.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

Review 6.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

7.  A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Authors:  Maria A Sullivan; Adam Bisaga; Martina Pavlicova; Kenneth M Carpenter; C Jean Choi; Kaitlyn Mishlen; Frances R Levin; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2018-10-19       Impact factor: 18.112

8.  National trends and characteristics of inpatient detoxification for drug use disorders in the United States.

Authors:  He Zhu; Li-Tzy Wu
Journal:  BMC Public Health       Date:  2018-08-29       Impact factor: 3.295

9.  First-time admissions for opioid treatment: cross-sectional and descriptive study of new opioid users seeking treatment.

Authors:  Gerardo Flórez; Ana López-Durán; Yolanda Triñanes; Jesús Osorio; Jaime Fraga; José Manuel Fernández; Elisardo Becoña; Manuel Arrojo
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-24       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.